Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2014, Vol. 19 ›› Issue (2): 176-179.

Previous Articles     Next Articles

PK-PD study on gemifloxacin mesylate against common pathogenic bacteria in urinary tract

REN Bin1, LIAO Kang1, LI Rui-ming1, FU Xiao-hua2, YE Yi-fang1, HONG Xiao-dan1   

  1. 1The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, Guangdong, China;
    2Guangzhou Xinhai Hospital, Guangzhou 510300, Guangdong, China
  • Received:2013-03-02 Revised:2014-02-11 Online:2014-02-26 Published:2014-03-31

Abstract: AIM: To carry out PK/PD study of gemifloxacin mesylate against common pathogenic bacteria in urinary tract.METHODS: MIC (minimum inhibitory concentration) and MBC (minimum bactericidal concentration) of gemifloxacin against common pathogenic bacteria in urinary tract were determined. Urine concentration of healthy subjects after oral administration of gemifloxacin mesylate tablets (320 mg) was determined and then Cmax/MIC90 and AUC24 h/MIC90 were calculated.RESULTS: Gemifloxacin had lower sensitivity to common pathogenic bacteria in urinary tract. Urinary peak concentration (Cmax) of gemifloxacin was(144±124) μg/mL and the area under urine concentration-time curve (AUC24 h) was(1368±671) μg·mL-1·h after orally administered gemifloxacin mesylate tablets (320 mg) to healthy subjects. Cmax/MIC90 of gemifloxacin in urine against Escherichia coli, Pseudomonas aeruginosa and Enterococcus faecalis was 2.9-5.8 and AUC24 h/MIC90 was more than 30, whereas AUC24 h/MIC90 of gemifloxacin against Klebsiella pneumoniae and Enrerococcus feces was 19.25.CONCLUSION: Gemifloxacin could effectively remove Escherichia coli, Pseudomonas aeruginosa and Enterococcus faecalis infected in urinary tract, and avoid resistance. Gemifloxacin could inhibit growth of Klebsiella pneumoniae and Enterococcus feces.

Key words: gemifloxacin mesylate, MIC, MBC, PK, PD

CLC Number: